

*Rs. in Lakhs*

		STANDALONE			
Sl. No.	PARTICULARS	For the Quarter Ended			For the Year Ended
		30/06/2022	31/03/2022	30/06/2021	31/03/2022
		UN-AUDITED	UN-AUDITED	UN-AUDITED	AUDITED
	(1)	(2)	(3)	(4)	
1	<b>Income</b>				
	Revenue from operations	33,879.91	36,384.72	26,380.13	1,32,022.21
	Other Income	1,089.75	13,439.58	578.29	18,778.80
	<b>Total income</b>	<b>34,969.66</b>	<b>49,824.30</b>	<b>26,958.42</b>	<b>1,50,801.01</b>
2	<b>Expenses</b>				
	a) Cost of materials consumed	11,229.40	13,027.81	9,183.96	45,945.64
	b) Purchases of stock-in-trade	-	-	-	-
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(1,564.13)	(1,994.03)	(1,508.91)	(6,035.21)
	d) Employee benefits expense	2,479.26	3,112.20	2,115.89	10,048.39
	e) R & D expense	223.23	214.42	235.24	1,035.45
	f) Finance costs	143.25	218.87	212.55	623.10
	g) Depreciation and amortisation expenses	1,054.78	1,042.08	899.33	3,909.71
	h) Manufacturing Expenses	4,138.69	4,434.34	3,884.83	17,318.86
	i) Other Expenses	1,899.49	1,833.11	1,007.47	5,710.25
	<b>Total expenses</b>	<b>19,603.97</b>	<b>21,888.80</b>	<b>16,030.36</b>	<b>78,556.19</b>
3	<b>Profit before exceptional items &amp; Tax (1-2)</b>	<b>15,365.69</b>	<b>27,935.50</b>	<b>10,928.06</b>	<b>72,244.82</b>
4	Exceptional Items	-	-	-	-
5	<b>Profit before Tax (3-4)</b>	<b>15,365.69</b>	<b>27,935.50</b>	<b>10,928.06</b>	<b>72,244.82</b>
6	Tax Expenses				
	a) Current tax	3,888.10	5,148.01	2,716.35	15,763.03
	b) Deferred tax	72.42	341.02	67.59	671.91
7	<b>Net Profit/ (Loss) for the period/year(5-6)</b>	<b>11,405.17</b>	<b>22,446.47</b>	<b>8,144.12</b>	<b>55,809.88</b>
8	<b>Other Comprehensive Income</b>				
8.a	(i) Items that will not be reclassified to profit or loss	(25.48)	(18.06)	(27.96)	(101.95)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	6.41	4.55	7.03	25.66
8.b	(i) Items that will be reclassified to profit or loss	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
	<b>Total other Comprehensive Income</b>	<b>(19.07)</b>	<b>(13.51)</b>	<b>(20.93)</b>	<b>(76.29)</b>
9	<b>Total Comprehensive Income for the period (7+8)</b>	<b>11,386.10</b>	<b>22,432.96</b>	<b>8,123.19</b>	<b>55,733.59</b>
10	Paid-up equity share capital Face Value of the Share	2,545.65 Re.1.00	2,545.65 Re.1.00	2,545.65 Re.1.00	2,545.65 Re.1.00
11	Other Equity	-	-	-	1,49,523.67
12	<b>Earning Per Share (EPS)-Face value of Rs.1/- each)</b>				
	a) Basic	4.48	8.82	3.20	21.92
	b) Diluted	4.48	8.82	3.20	21.92
		(not annualised)	(not annualised)	(not annualised)	

		<b>CONSOLIDATED</b>			
Sl. No.	PARTICULARS	For the Quarter Ended			For the Year Ended
		30/06/2022	31/03/2022	30/06/2021	31/03/2022
		UN-AUDITED	UN-AUDITED	UN-AUDITED	AUDITED
		(1)	(2)	(3)	(4)
1	<b>Income</b>				
	Revenue from operations	33,879.91	36,384.72	26,380.13	1,32,022.21
	Other Income	1,103.31	1,687.12	578.29	9,238.03
	<b>Total income</b>	<b>34,983.22</b>	<b>38,071.84</b>	<b>26,958.42</b>	<b>1,41,260.24</b>
2	<b>Expenses</b>				
	a) Cost of materials consumed	11,273.55	13,027.81	9,183.96	45,945.64
	b) Purchases of stock-in-trade		-	-	
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(1,564.13)	(1,994.03)	(1,508.91)	(6,035.21)
	d) Employee benefits expense	2,658.56	3,112.20	2,115.89	10,048.39
	e) R & D expense	223.23	214.42	235.24	1,035.45
	f) Finance costs	145.16	218.87	212.55	623.10
	g) Depreciation and amortisation expense	1,150.46	1,042.08	899.33	3,909.71
	h) Manufacturing Expenses	4,230.95	4,434.34	3,884.83	17,318.86
	i) Other Expenses	1,969.53	1,887.94	1,008.18	5,766.55
	<b>Total expenses</b>	<b>20,087.31</b>	<b>21,943.63</b>	<b>16,031.07</b>	<b>78,612.49</b>
3	<b>Profit before exceptional items, Tax &amp; share in profit/(Loss) of Associates (1-2)</b>	<b>14,895.91</b>	<b>16,128.21</b>	<b>10,927.35</b>	<b>62,647.75</b>
4	<b>Add : Share of profit/(Loss) of Associates.</b>	<b>-</b>	<b>-</b>	<b>2,364.90</b>	<b>4,111.23</b>
5	<b>Profit before exceptional items, Tax (3+4)</b>	<b>14,895.91</b>	<b>16,128.21</b>	<b>13,292.25</b>	<b>66,758.98</b>
6	Exceptional Items	-	-	-	-
7	<b>Profit before Tax (5-6)</b>	<b>14,895.91</b>	<b>16,128.21</b>	<b>13,292.25</b>	<b>66,758.98</b>
8	Tax Expenses				
	a) Current tax	4,069.28	5,964.54	2,716.35	19,040.47
	b) Deferred tax	72.42	996.87	67.59	2,338.02
9	<b>Net Profit/ (Loss) for the period/year(7-8)</b>	<b>10,754.21</b>	<b>9,166.80</b>	<b>10,508.31</b>	<b>45,380.49</b>
10	<b>Other Comprehensive Income</b>				
10.a	(i) Items that will not be reclassified to profit or loss	(25.57)	(18.06)	(27.96)	(101.95)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	6.41	4.55	7.03	25.66
10.b	(i) Items that will be reclassified to profit or loss	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
	<b>Total other Comprehensive Income</b>	<b>(19.16)</b>	<b>(13.51)</b>	<b>(20.93)</b>	<b>(76.29)</b>
11	<b>Total Comprehensive Income for the period (9 + 10)</b>	<b>10,735.05</b>	<b>9,153.29</b>	<b>10,487.38</b>	<b>45,304.20</b>
12	Paid-up equity share capital	2,545.65	2,545.65	2,545.65	2,545.65
	Face Value of the Share	Re.1.00	Re.1.00	Re.1.00	Re.1.00
13	Other Equity	-	-	-	1,50,172.39
14	<b>Earning Per Share (EPS)- (Face value of Rs.1/- each)</b>				
	a) Basic -	4.22	3.60	4.13	17.83
	b) Diluted	4.22	3.60	4.13	17.83
		(not annualised)	(not annualised)	(not annualised)	(annualised)

- Notes**
- 1) The above financial results of the Company have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 8th Aug, 2022. The above results have been subjected to limited review by the statutory auditors of the company
  - 2) The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended, prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder.
  - 3) The consolidated financial results include the results of the wholly owned subsidiaries Suven Pharma, Inc., USA & Casper Pharma Pvt Ltd, w.e.f. from 22nd April '2022
  - 4) The Company reportable activity falls under single business segment and hence, segment reporting as per IND AS 108 (Operating Segment) is not presented.
  - 5) The other Income ( Standalone figures for the year-2021-22 includes an amount of Rs.15081.85 Lacs (Q3 Rs.3329.39 lacs & Q4 Rs.11752.46 lacs) pertaining to the Dividends received and Rs.1080.41 lacs pertaining to Gain on Investments on part disinvestment of Capital from our Subsidiary ,Suven pharma ,Inc . The Current tax for the year 2021-22 (Standalone figures) includes an amount of Rs.1676.21 lacs (Q3 Rs.491.72 Lacs & Q4 Rs.1184.49 Lacs ) withholding tax paid on Such Dividend by our subsidiary.
  - 6) The Suven Pharma Inc., the WOS of our Company has divested it's entire stake (25% amounting to \$35.00 Mn) in M/s Rising Pharma Holdings, Inc., USA on 13th Dec, 2021 to Raisin Acquisition Co, Inc., one of the investment arms of H.I.G. Capital, a leading global alternative investment firm in USA through structured deal. As part of the structured deal our WOS, Suven Pharma, Inc., received in the form of cash component of \$ 41.555 Mn and a stake valued at \$15.803 Mn in Raisin Aggregators L.P. Accordingly , Rising Pharma Holdings, Inc., USA has ceased to be an associate company w.e.f 13th Dec' 2021. Hence, the share of profits of associate has not been considered in the consolidated financial statements for the Quarter ended 31st Mar' 2022.
  - 7) Post approval of the Board in the meeting held on 5th April 2022, the company has completed acquisition of 100% stake in Casper Pharma Pvt Ltd, ( SEZ company )engaged in formulations business for USD 20.50Min and has become a Wholly Owned Subsidiary of the Company w.e.f 22nd April 2022. Subsequently subscribed the right issue in the ratio of 4:1 on 22/06/2022 of 52,16,156 shares of face value of Rs.10.00 with a premium of Rs.70.00 per share for Rs.4172.92 Lacs.
  - 8) The US Food and Drug Administration (USFDA) completed pre-approval inspection at Casper Pharma formulations manufacturing facility. The inspection was conducted from 25 through 29, July 2022. The audit was part of the agency's inspection for three product applications filed and slated to be manufactured at this site. The audit completed successfully with Zero observations and at the end of the inspection no form 483 was issued by USFDA.
  - 9) The corresponding previous period figures have been regrouped/reclassified where ever necessary.

**For SUVEN PHARMACEUTICALS LTD**

Place : Hyderabad  
Date: 8thAugust 2022

**VENKAT JASTI**  
**Managing Director**  
**DIN: 00278028**